These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 33559417)
21. Niraparib: A Review in Ovarian Cancer. Heo YA; Duggan ST Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633 [TBL] [Abstract][Full Text] [Related]
22. Niraparib for the treatment of ovarian cancer. Essel KG; Moore KN Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447 [TBL] [Abstract][Full Text] [Related]
23. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768 [TBL] [Abstract][Full Text] [Related]
25. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391 [TBL] [Abstract][Full Text] [Related]
28. Niraparib for the treatment of ovarian cancer. Kanjanapan Y; Lheureux S; Oza AM Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955 [TBL] [Abstract][Full Text] [Related]
29. Niraparib - A promising drug with hematological toxicity. Patibandla NS; Monga DK J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481 [TBL] [Abstract][Full Text] [Related]
30. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175 [TBL] [Abstract][Full Text] [Related]
31. Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". McQueen RB; Whittington MD; Chapman RH; Kumar VM; Campbell JD Pharmacoeconomics; 2019 Jul; 37(7):963-964. PubMed ID: 31044348 [No Abstract] [Full Text] [Related]
32. Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". Wallace K; Goble S; Isaacson J; Maloney L; Cameron T; Bedel J Pharmacoeconomics; 2019 Aug; 37(8):1065-1067. PubMed ID: 31172449 [No Abstract] [Full Text] [Related]
33. Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'. Guy H; Walder L; Fisher M Pharmacoeconomics; 2019 Jul; 37(7):965-967. PubMed ID: 31044349 [No Abstract] [Full Text] [Related]
34. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410 [TBL] [Abstract][Full Text] [Related]
35. Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series. Gabrail N; Smith C Am J Case Rep; 2020 Nov; 21():e927008. PubMed ID: 33191394 [TBL] [Abstract][Full Text] [Related]
36. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Kurnit KC; Coleman RL; Westin SN Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808 [TBL] [Abstract][Full Text] [Related]